An Experimental Surgery Is Helping Cancer Survivors Give Birth

Why It Matters

By safeguarding reproductive capacity, the surgery offers young pelvic cancer survivors a chance at natural pregnancy, addressing a major quality‑of‑life concern. Its success could reshape fertility preservation standards and stimulate broader adoption of organ‑sparing techniques.

Key Takeaways

• Uterus, ovaries temporarily relocated during pelvic cancer treatment
• Procedure enabled five births, including first in Europe
• Surgeons performed ~16 cases; ~40 worldwide estimated
• Risks include organ damage, potential cancer spread
• Technique remains experimental; standardized protocol not yet established

Pulse Analysis

Radiation and chemotherapy for rectal or other pelvic cancers often irreversibly damage the uterus and ovaries, leaving survivors with limited options for childbearing. Conventional fertility preservation relies on egg or embryo freezing, which does not address uterine loss, and surrogacy is prohibited in many jurisdictions, including Switzerland. The experimental organ‑relocation surgery directly tackles this gap by moving the reproductive tract out of the radiation field, preserving both gamete viability and uterine function. This approach reframes fertility preservation from a purely gamete‑centric model to a holistic, organ‑sparing strategy.

The technique, first reported in 2017 by Dr. Reitan Ribeiro and later refined by surgeons such as Dr. Daniela Huber, involves suturing the uterus, fallopian tubes and ovaries to the upper abdominal wall before oncologic treatment, then re‑implanting them once therapy concludes. Procedures typically last two to three hours, with stitches removed after a week to allow scar tissue anchorage. To date, roughly 16 documented surgeries have produced at least six healthy births across Europe, North America, Israel and other regions, though isolated failures and risks of organ injury remain. Ongoing data collection aims to standardize protocols and define patient selection criteria.

As more centers adopt the method, the procedure could shift clinical guidelines for young women facing pelvic malignancies, offering a realistic path to natural pregnancy. However, widespread implementation will require rigorous long‑term outcome studies, clear regulatory pathways, and multidisciplinary coordination between oncologists, reproductive specialists and surgeons. Ethical considerations around experimental fertility interventions also demand transparent patient counseling. If validated, organ relocation may become a cornerstone of fertility‑preserving oncology, reducing the psychosocial burden of cancer survivorship and expanding reproductive autonomy.